Bad Radkersburg

Researchers are evaluating the DynamX Coronary Bioadaptor System in patients with coronary artery disease caused by new native coronary artery lesions. This registry aims to confirm the safety, effectiveness, and performance of this device in a real-world patient population. The study focuses on patients who require percutaneous coronary intervention (PCI) with stent implantation. All participants will receive at least one DynamX Novolimus-eluting Coronary Bioadaptor implant following the product's Instructions for Use. The treatment is provided in a commercial setting as part of routine clinical care. This registry collects additional data on the device's performance and safety over time in patients undergoing this procedure. Participants will be monitored for at least 12 months to assess device-oriented clinical outcomes. Researchers will collect data on safety and effectiveness during this period. Patient involvement includes providing informed consent and complying with study procedures. The total duration of participation is based on the 12-month follow-up for clinical endpoints.

Researchers are evaluating the effectiveness of brenetafusp (IMC-F106C) combined with nivolumab compared to standard nivolumab treatments in people who have advanced melanoma that has not been treated before. This study focuses on participants who have a specific genetic marker called HLA-A*02:01 and aims to understand how these treatments affect the progression of their cancer. The study is a phase 3, randomized, controlled trial, which helps ensure reliable comparison between the different treatment regimens. Participants in this study will receive either brenetafusp plus nivolumab or standard nivolumab regimens, which may include nivolumab alone or in combination with relatlimab. These treatments are given by intravenous infusion, with specific dosing of the drugs as concentrates for infusion. The study compares these approaches to see which is more effective in controlling the melanoma. During the study, participants will be closely monitored for disease progression and overall health. Researchers will use scans and other assessments to measure progression-free survival, which is the time participants live without their disease worsening, followed for up to about 45 months. Safety and response to treatment will be regularly evaluated to better understand the effects of the therapies over time.